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Abstract 
The optimal hemoglobin level in patients with hypertension or heart failure is not yet defined. The aim 
of the present investigation was to examine the relation of hemoglobin with cardiovascular outcomes in 
high-risk patients with isolated systolic hypertension (ISH) and left ventricular hypertrophy (LVH). In 
1326 patients with ISH in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) 
study, hemoglobin and cardiovascular outcomes were examined using Cox proportional hazard models. 
Baseline hemoglobin was negatively related to the rate of cardiovascular death (hazard ratio 0.81 [95% 
CI 0.67-0.98] per 1 g/dL, p = 0.032) after adjusting for baseline Framingham risk score (FRS), LVH, 
treatment, and estimated glomerular filtration rate (eGFR). Hemoglobin decreased slightly during the 
study and the decline was more pronounced in the losartan group (13.9 ± 1.3 g/dL to 13.6 ±1.4 g/dL) 
than in the atenolol group (13.9 ± 1.2 g/dL to 13.8 ± 1.4 g/dL). Hemoglobin as a time-varying covariate 
was negatively associated with the rate of cardiovascular death (hazard ratio 0.75 [0.63-0.90], p < 0.001) 
and stroke (hazard ratio 0.84 [0.72-0.99], p = 0.040), after adjusting for baseline FRS, LVH, treatment, 
and eGFR. In conclusion, in this high-risk population with ISH and LVH, lower hemoglobin at baseline 
was associated with higher probability of cardiovascular death, and fall in hemoglobin over time was 
associated with higher probability of cardiovascular death or stroke and this effect was attenuated by 
treatment with losartan. 
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Introduction 
Hemoglobin can effect peripheral vascular resistance in 2 ways according to the Poiseuille-
Hagen equation: primarily by influencing the viscosity of blood,1 and secondarily by affecting 
the caliber of peripheral arterioles.2 High hemoglobin levels have been related to increased 
cardiovascular risk3 and may induce left ventricular hypertrophy (LVH) in patients with 
hypertension.4 On the other hand, low hemoglobin levels are also associated with cardiovascular 
risk. The potentially harmful effect of anemia has been shown in the general population5 and in 
patients with heart failure.6 Little is known about hemoglobin levels and cardiovascular outcome 
in the hypertensive population. In the Losartan Intervention For Endpoint reduction in 
hypertension (LIFE) study, the effects of losartan were compared with atenolol in the context of 
comparable blood-pressure lowering.7 The aim of the present study was to investigate the 
relation between hemoglobin and cardiovascular outcomes in this prespecified group of well-
characterized hypertensive subjects with high cardiovascular risk.   
 
Methods 
Study design and organization: The LIFE study was a prospective, multinational, 
multicenter, double-blind, double-dummy, randomized, active-controlled, parallel-group study. 
The primary objective was to evaluate the long-term effects of losartan- compared with atenolol-
based antihypertensive therapy in patients with hypertension and electrocardiographically (ECG) 
documented LVH on the incidence of cardiovascular morbidity and mortality. The LIFE study 
design, organization, clinical measures, endpoint definitions, basis for choice of comparative 
agents, statistical power calculations, recruitment details, baseline characteristics, 1-year follow-
up, and primary results have been published.7-11 Hemoglobin levels were obtained at baseline 
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immediately prior to randomization and at annual clinic visits. The trial protocol was approved 
by local ethics committees and performed in accordance with the Declaration of Helsinki. The 
study was overseen by an independent data and safety monitoring board. All participants gave 
written informed consent. 
Target population and treatment schedule: Persons aged 55 to 80 years with 
previously treated or untreated hypertension and ECG evidence of LVH were enrolled in the 
LIFE study. Those with secondary hypertension; myocardial infarction or stroke within the 
previous 6 months; angina pectoris requiring treatment with β-blockers or calcium antagonists; 
active heart failure or known left ventricular ejection fraction  40%; or a disorder that, according 
to the treating physician’s opinion, required treatment with open- label study medication or 
related drugs were excluded. Also excluded were patients with serum creatinine >1.8 mg/dL 
(160 µmol/L), a solitary kidney, or kidney transplant. Eligible persons were randomly assigned 
to losartan- or atenolol-based regimens after 1 or 2 weeks of placebo if trough sitting blood 
pressures were 160-200 mm Hg systolic, 95-115 mm Hg diastolic, or both. In this analysis, the 
patients had trough sitting blood pressure between 160-200 mm Hg systolic with diastolic 
pressure <90 mm Hg.12 From July 6, 1995, through May 2, 1997, a total of 1326 patients with 
ISH were randomized to treatment in the LIFE study.12 Patients were followed for 4 or more 
years with regular visits and upward titration of medication to reach a goal systolic blood 
pressure of <140 mm Hg. Only 2 patients (0.2%) with ISH were lost to follow-up. 
ECG coding and LVH criteria: All ECGs were evaluated at a central core reading 
center for LVH criteria and Minnesota Codes. ECG-LVH was measured using gender-adjusted 
Cornell product criteria (RaVL + SV3 [+6 mm in women] x QRS duration) >2440 mm•msec or 
Sokolow-Lyon voltage (SV1 + RV5/6) >38 mm.
8, 13-15  
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Outcome measures: The primary endpoint was a composite of cardiovascular death, 
fatal or non-fatal stroke, and fatal or non-fatal myocardial infarction. Other prespecified outcome 
measures were components of the primary composite endpoint, total mortality, hospitalization 
for angina pectoris, hospitalization for heart failure, coronary or peripheral revascularization 
procedures, resuscitated cardiac arrest, and new-onset diabetes mellitus.7 Routine laboratory tests 
were performed in 2 central laboratories. The study ran its full course and endpoint follow-up 
was stopped on September 16, 2001.7  
Statistical methods: The prespecified data analysis plan for the LIFE study highlighted 
ISH as being of particular interest and indicated that all endpoint analyses were to be performed 
in this subgroup. The study of the effect of hemoglobin in the ISH population is post hoc. 
Hemoglobin level is expressed as mean (standard deviation). All cardiovascular endpoints and 
blood pressures were analyzed using the intention-to-treat approach. Participants who 
experienced >1 endpoint were counted as having an event in all relevant endpoint analyses; 
however, only the first event in a specific category was counted in individual analyses. The 
associations between hemoglobin and cardiovascular outcomes were examined using Cox 
proportional hazard models using hemoglobin as a continuous variable or stratified by 
hemoglobin quintiles. The models were adjusted for Framingham risk score, LVH, treatment, 
and estimated glomerular filtration rate (eGFR) calculated by using the abbreviated Modification 
of Diet in Renal Disease study (MDRD) equation.16 The time-varying hemoglobin analyses 
included all of the hemoglobin values that were observed before an endpoint and the time 
between those values as covariates in the Cox regression models. 
 
Results 
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Patient characteristics: Of the 9193 patients participating in the LIFE study, 1326 
fulfilled the criteria necessary for inclusion in this analysis. Patients did not have serious renal 
dysfunction (baseline mean serum creatinine 0.98 + 0.23 mg/dL [86.9 + 20.2 µmol/L]). 
Compared with the overall LIFE population, patients in the LIFE ISH subgroup were older, had 
lower diastolic blood pressure, and higher prevalences of coronary heart disease, cerebrovascular 
disease, peripheral vascular disease, atrial fibrillation, and diabetes at baseline. The mean age 
was 70 ± 6 years; 60% of patients were women; 92% were white and 6% black; 18% had 
diabetes; and mean blood pressure was 174 ± 11/83 ± 6 mm Hg. When anemia was defined as 
hemoglobin <13.8 g/dL for males or <12.1 g/dL for females, the distribution of baseline anemia 
was significantly different (p < 0.0001) between males and females: 23.6% (111 out of 470) of 
males and 7.6% (55 out of 722) of females had anemia at baseline. Additional baseline 
characteristics for the ISH subgroup are presented in Table 1, and are similar in the losartan and 
atenolol groups. Cardiovascular events and treatment effects in the ISH subgroup of LIFE have 
been published.12 The treatment benefits of losartan were more pronounced for the primary 
composite endpoint, cardiovascular death, and stroke than for myocardial infarction. 
Hemoglobin and endpoints: Hemoglobin decreased in both treatment groups during the 
study, more so in the losartan group (13.9 ± 1.3 g/dL to 13.6 ± 1.4 g/dL) than in the atenolol group (13.9 
± 1.2 g/dL to 13.8 ± 1.4 g/dL) (Figure 1).  
Baseline hemoglobin was negatively related to the rate of cardiovascular death (hazard ratio 0.81 
[95% CI 0.67-0.98] per 1 g/dL, p = 0.032) after adjusting for baseline Framingham risk score, treatment 
LVH, and eGFR. Results were also examined by quintiles of baseline hemoglobin level, where the 
reference group was the lowest quintile of hemoglobin ( 12.9 g/dL) (Figure 2). There were negative 
relations between hemoglobin levels at baseline over the range of levels observed in this study and the 
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primary composite endpoint, cardiovascular death, and stroke, but there was a minimally higher rate of 
myocardial infarction in the highest hemoglobin quintile (Figure 2). Hemoglobin as a time-varying 
covariate was negatively associated with the rate of cardiovascular death (hazard ratio 0.75 [0.63-0.90], 
p < 0.001) and stroke (hazard ratio 0.84 [0.72-0.99], p = 0.040) after adjusting for baseline Framingham 
risk score, LVH, treatment, and eGFR (Table 2). These associations were also significant for the 
unadjusted analysis for cardiovascular death, and for the primary composite endpoint, stroke, and 
cardiovascular death when adjusted for baseline Framingham risk score and LVH (Table 2).  
 
Discussion 
In the present investigation of high-risk patients with ISH and LVH, we found that lower 
hemoglobin during follow-up was significantly related to a higher rate of the LIFE primary 
composite endpoint of cardiovascular death, fatal and non-fatal stroke, and fatal and non-fatal 
myocardial infarction, after adjustment for Framingham risk score and LVH. Lower follow-up 
hemoglobin was of borderline significance when treatment and eGFR were also added to the 
model. Lower follow-up hemoglobin was significantly related to cardiovascular death and stroke 
in both sets of covariate adjustments (i.e., Framingham risk and LVH with or without treatment 
and eGFR). When considered separately with adjustment for covariates, a 25% lower relative 
risk of cardiovascular death and a 19% lower risk of stroke was detected per g/dL higher 
hemoglobin. The association of higher hemoglobin with fewer cardiovascular events did not 
show a clear threshold level in this population, nor was any U- or J-shaped relation detected. The 
patients treated with the losartan-based regimen had a larger decrease in hemoglobin than the 
patients on the atenolol-based regimen, consistent with the results of Robles et al.17. The 
statistical significance of benefits associated with losartan-based therapy previously reported in 
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the LIFE ISH substudy12 was sustained or even modestly enhanced in the present analyses that 
also took time-varying hemoglobin into account. In addition, the present results in the subset of 
the LIFE population with ISH confirm the finding of the association of low hemoglobin with 
several endpoints, including all-cause mortality, in a preliminary analysis of the entire LIFE 
study population.18 
The World Health Organization defines anemia as hemoglobin concentration <13.0 g/dL 
for men and post-menopausal women, and <12.0 g/dL for pre-menopausal women.19 Among 
otherwise healthy individuals, anemia is well tolerated because of compensating mechanisms, 
and optimal hemoglobin level is a matter of debate. Still, in the Atherosclerosis Risk in 
Communities (ARIC) study,5 a clear relation between risk for cardiovascular disease and lower 
hemoglobin levels in both women and men was revealed. In chronic kidney disease, however, no 
benefit of complete correction of anemia has been seen.20-21 
 Some limitations to these analyses need to be mentioned. The LIFE study population was 
of older age and mainly white ethnicity. LIFE enrolled patients with hypertension and ECG-
LVH, a population at high risk for cardiovascular events. Analyses of patients with ISH in LIFE 
are subgroup analyses of the LIFE population, although the ISH group was selected a priori as 
being of special interest.  
In conclusion, while lower hemoglobin at baseline or fall in hemoglobin over time are 
associated with higher probability of outcomes, this was attenuated by treatment with losartan in 
the LIFE study. This observation does not suggest that attempting to increase hemoglobin in this 
cohort is warranted. This analysis confirms previous studies that describe lower hemoglobin, 
even at the low normal range, as an adverse prognostic sign.  
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Figure 1. Summary of hemoglobin level at different time points by treatment. 
 
Figure 2. Results obtained from Cox proportional hazard model with baseline 
hemoglobin quintiles and with adjustment for baseline Framingham risk score, treatment, 
and estimated glomerular filtration rate. Comparison is with the lowest quintile of 
hemoglobin ( 12.9 g/dL). 
 
 
CI = confidence interval 
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Table 1 
Baseline characteristics of LIFE patients with isolated systolic hypertension12 
 
Variable 
Losartan 
(n = 660) 
Atenolol 
(n = 666) 
All 
(n = 1326) 
Age (years) 70.2 (6.4) 70.4 (6.3) 70.3 (6.3) 
Female 388 (58.8%) 408 (61.3%) 796 (60.0%) 
Ethnic origin    
  White  606 (91.8%) 617 (92.6%) 1223 (92.2%) 
  Black  44 (6.7%) 37 (5.6%) 81 (6.1%) 
  Hispanic  5 (0.8%) 9 (1.4%) 14 (1.1%) 
  Asian  4 (0.6%) 2 (0.3%) 6 (0.5%) 
  Other  1 (0.2%) 1 (0.2%) 2 (0.2%) 
Blood pressure (mm Hg)  174.2/83.0 (10.7/5.4) 174.5/82.3 (11.0/6.2) 174.4/82.6 (10.9/5.8) 
Heart rate (beats/min)  71.5 (10.3) 71.5 (11.3) 71.5 (10.8) 
Body mass index (kg/m2) 27.2 (4.6) 27.7 (5.2) 27.5 (4.9) 
Cornell voltage-duration product 
(mm•msec)  
2771.9 (1077.8) 2820.2 (1157.0) 2795.6 (1118.1) 
Sokolow-Lyon (mm)  30.8 (10.5) 31.4 (10.6) 31.1 (10.6) 
Framingham risk score 0.230 (0.103) 0.238 (0.098) 0.232 (0.101) 
Current smokers 95 (14.4%) 102 (15.4%) 197 (14.9%) 
Previously untreated 233 (35.3%) 211 (31.7%) 444 (33.5%) 
Coronary heart disease 158 (23.9%) 140 (21.0%) 298 (22.5%) 
Cerebrovascular disease 70 (10.6%) 86 (12.9%) 156 (11.8%) 
Peripheral vascular disease 57 (8.6%) 55 (8.3%) 112 (8.4%) 
Atrial fibrillation 28 (4.2%) 39 (5.9%) 67 (5.1%) 
Diabetes 103 (15.6%) 131 (19.7%) 234 (17.6%) 
Hemoglobin (gm/dL) 13.86 (1.27) 13.90 (1.21) 13.88 (1.24) 
Serum creatinine (micromol/L) 89.13 (22.27) 87.50 (19.91) 88.31 (21.12) 
eGFR (mL/min/1.73 m2) 70.21 (16.09) 70.36 (15.57) 70.29 (15.82) 
 
eGFR = estimated glomerular filtration rate 
  15 
Table 2 
Effect of time-varying hemoglobin on cardiovascular endpoints 
  
Unadjusted 
HR (95% CI) 
Adjusted  
for baseline FRS + LVH 
HR (95% CI) 
Adjusted  
for baseline FRS + LVH+ treatment + 
eGFR 
HR (95% CI) 
Primary composite endpoint 0.95 (0.84-1.07) 
p=0.371 
0.89 (0.79-1.00) 
p=0.046 
0.90 (0.80, 1.01)  
p=0.077 
Cardiovascular death 0.83 (0.70-0.99) 
p=0.034 
0.79 (0.67-0.93) 
p=0.005 
0.75 (0.63-0.90)  
p=0.001 
Stroke 0.87 (0.74-1.02) 
p=0.093 
0.83 (0.71-0.97) 
p=0.020 
0.84 (0.72-0.99) 
p=0.040 
Myocardial infarction  1.08 (0.89-1.31) 
p=0.437 
1.02 (0.84-1.24) 
p=0.831 
1.02 (0.83-1.25) 
p=0.854 
 
CI = confidence interval; eGFR = estimated glomerular filtration rate; FRS = Framingham risk score; HR = hazard ratio per g/dL of hemoglobin. 
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Figure 1. Summary of hemoglobin level (mean ± SD)  at different time points by treatment  
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Figure 2. Results obtained from Cox proportional hazard model with baseline 
hemoglobin quintiles and with adjustment for baseline Framingham risk score, treatment, 
and estimated glomerular filtration rate. Comparison is with the lowest quintile of 
hemoglobin ( 12.9 g/dL). 
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